ASMB News & Events

Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus infection, into primary biliary cholangitis and primary sclerosing cholangitis, broadening the program into cholestatic liver diseases. "We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant unmet medical need despite existing PBC therapies, and in the case of PSC, no approved treatments," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "The NTCP receptor plays an integral role in both HDV entry and bile acid transport into liver cells, making it a compelling target across multiple liver diseases. We believe ABI-6250 has the potential to address key drivers of disease pathology in these conditions and look forward to advancing clinical evaluation in these populations."

Reports Q1 revenue $8.21M, consensus $6.95M. "The first quarter reflected steady progress across our portfolio as we continue advancing our discovery and development programs," said Jason Okazaki, chief executive officer and president of Assembly Bio. "As we look ahead, we anticipate receiving Gilead's development plan and budget for the herpesvirus program and will evaluate our cost and profit share opt-in decision by mid-2026 while continuing to advance ABI-6250 toward Phase 2 in hepatitis delta virus by year-end."

Assembly Biosciences files $400M mixed securities shelf